A Phase 3 interventional study of Finerenone and Placebo Finerenone in Chronic Kidney Diseases, sponsored by The George Institute. Recruiting at 51 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-05.
Sponsored by The George Institute · Phase 3, Interventional, and Treatment
How we know · 6 judgments
…and 1 more changes, on the record history on ClinicalTrials.gov ↗
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies testing finerenone in Renal Insufficiency, Chronic — 14 open to participants now, 16 under way, 4 of them phase 3. finerenone · Renal Insufficiency, Chronic.
Among the 25 studies testing finerenone in Renal Insufficiency, Chronic, this one is the 2nd largest by planned enrollment, is one of 5 that started in 2024, is one of 6 in phase 3, reaches primary completion later than 15 of the 15 other live ones, and was the 10th registered.
3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.
Browse Renal Insufficiency, Chronic studies →14 of the 25 studies testing finerenone in Renal Insufficiency, Chronic are open now, in 12 countries. Recruiting first, the newest first:
Peter Rossing · Sites in Denmark, Germany, Spain and 1 more country
Ages 18–75
Chinese University of Hong Kong · Sites in Hong Kong
Ages 18+
University of Aarhus · Sites in Denmark
Ages 18+
Bayer · Sites in United States, Argentina, Australia and 29 more countries
Ages 1–18
Baylor Research Institute · Sites in United States
Ages 18–84
By country, each count listing its studies:
finerenone: first FDA approval 2021 (KERENDIA), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →
Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 5 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,000 is above the median of 73 across 2,164 interventional studies indexed under Renal Insufficiency, Chronic.
Median enrollment 100 across the 25 interventional studies. Of the 9 that completed or were terminated, 4 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 25 have an industry lead sponsor. The 10 most frequent:
The George Institute is the lead sponsor of 57 studies on the registry; 13 are open to participants now.
The George Institute has 3 studies filed under Renal Insufficiency, Chronic — fewer than ten, so there is no comparison to draw.
6 of the studies testing finerenone in Renal Insufficiency, Chronic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05196035Phase 3BayerA Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria | 2027-04-10 |
| NCT07235891Alexandria UniversityRetinal Protective Effects of Novel Finerenone in Patients With Chronic Kidney Disease | 2026-12-20 |
| NCT07026539University of AarhusEffect of Treatment With Finerenone on Cardio-Renal Target Organ Damage in Patients With Type 2 Diabetes. | 2026-12-31 |
| NCT07849348Peking University People's HospitalStudy on the Efficacy and Safety of Initial Combination of Finerenone and Semaglutide in Non-Diabetic Adult Patients With Obesity Complicated by Chronic Kidney Disease With Albuminuria | 2027-02 |
| NCT07155694Washington D.C. Veterans Affairs Medical CenterRole of Finerenone in African American Veterans With Diabetic Kidney Disease | 2027-07 |
Add all 6 to your calendar (.ics) → With an account.
Among the 25 studies testing finerenone in Renal Insufficiency, Chronic, from their registry updates:
This tab as a report to print or save as PDF → With an account.
CAPTIVATE is an international, multi-centre, Phase III, adaptive, platform, randomised controlled trial in people with chronic kidney disease (CKD).
CAPTIVATE aims to find the best treatment, or combination of treatments, that slow the progression of CKD so that fewer people develop kidney failure.
CAPTIVATE provides a research platform that allows many treatment-related questions to be answered within a common trial set-up.
CAPTIVATE includes multiple domains examining different therapies for CKD. Participants may enrol in one or more domains and domains will be added and closed over time. The platform operates under a core protocol with each domain described in a domain specific appendix.
Chronic kidney disease (CKD) affects over 800 million people globally and is projected to be the 5th most common cause of death by 2040. CKD progresses to kidney failure, increases the risk of early death, heart disease, and leads to a poorer quality of life.
Current treatments do not entirely remove the risk of kidney failure in people with CKD. To improve the outcomes of people with CKD, it is crucial to find the best treatment or combination of treatments that can slow CKD progression. CAPTIVATE aims to address this need.
CAPTIVATE has been designed to test multiple treatments within a common research platform. This design is more efficient and will lead to a shorter time for patients to receive effective treatments. The trial is 'eternal', which means that participants will continue to be recruited for many years until the trial is finally wound up. It is also 'adaptive', providing the flexibility to add new treatments, or remove those that are not working.
Participants can participate in more than one treatment at the same time or at different times. Participants receive each study treatment for 2 years. For each treatment, participants are followed up at study visits that occur at approximately one month, 3 months, 6 months, 12 months, 18 months and 2 years after starting treatment. A final study visit occurs one month after the end of the 2-year treatment phase. Information collected at study visits include blood and urine test results, safety assessments and treatment adherence. Information about the overall health status of each participant is collected every 5 years.
The criteria were revised on the registry on Oct 5, 2026. See what changed
Inclusion Criteria:
Exclusion Criteria:
To be included in any of the following DOMAINS the participant must met eligible for the PLATFORM (as listed above)
MRA domain
Inclusion Criteria:
Exclusion Criteria:
GLP-1 RA Domain
Inclusion Criteria
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Finerenone 10mg or 20mg tablets
Drug: Finerenone
Finerenone matched placebo tablets
Drug: Placebo Finerenone
Semaglutide 1.0 mg or 2.4 mg pen injector
Drug: Semaglutide
Semaglutide matched placebo pen injector
Drug: Placebo semaglutide
Finerenone 10mg or 20mg tablets, oral, once daily
Also known as: BAY94-8862
Finerenone matched placebo tablets, oral, once daily
Semaglutide 1.0mg or 2.4mg pen injector, subcutaneous injection, once weekly
Semaglutide matched pen injector, subcutaneous injection, once weekly
Core Primary Outcome Measure
The primary outcome is chronic eGFR slope. Chronic eGFR slope measures the rate of eGFR decline while on treatment. The duration of time over which chronic eGFR slope is computed can vary by domain and is determined by clinical considerations such as whether the investigational product can cause an acute decline in eGFR upon initiation. DSAs will specify the duration of time over which chronic eGFR slope is computed for the individual domain.
Time frame: From randomisation to week 108
MRA Domain Primary Outcome Measure
Chronic eGFR slope estimated from all available eGFR values from week 4 to the end of treatment. The final eGFR value that contributes to the primary outcome is the last eGFR measured while the participant is on treatment.
Time frame: From week 4 to week 108
GLP1-RA Domain Primary Outcome Measure
Chronic eGFR slope estimated from all available eGFR values from Week 0 to the end of treatment. The final eGFR value that contributes to the primary outcome is the last eGFR measured while the participant is on treatment.
Time frame: From week 0 to week 108
Core Protocol Secondary outcomes
1\. Change in albuminuria as measured by uACR (or uPCR if uACR unavailable) between week 0 and 24 weeks, measured as a continuous variable.
Time frame: week 0 and 24 weeks
Core Protocol Secondary outcomes
2\. eGFR slope from week 0 to end of washout
Time frame: week 0 to end of washout
Core Protocol Secondary outcomes
3\. Change in eGFR from week 0 to end of washout
Time frame: week 0 to end of washout
Core Protocol Secondary outcomes
4\. Composite outcome of proportion of participants experiencing a ≥40% eGFR decline between week 0 and 108 weeks, and proportion of participants developing kidney failure (defined as eGFR \<15 mL/min/1.73m2 or chronic kidney replacement therapy start†) at 108 weeks.
Time frame: between week 0 and 108 weeks
Core Protocol Secondary outcomes
5\. Time to a composite outcome of ≥40% eGFR decline from week 0 or kidney failure
Time frame: from start of study drug (week 0) to washout (week 108) or kidney failure
Core Protocol Secondary outcomes
6\. All-cause mortality at 108 weeks
Time frame: at 108 weeks
Core Protocol Secondary outcomes
7\. Proportion of participants experiencing one or more cardiovascular events (cardiovascular death, hospitalised heart failure, myocardial infarction, stroke)\* between week 0 and week 108
Time frame: between week 0 and week 108
Core Protocol Secondary outcomes
8\. Time to first occurrence of a cardiovascular event
Time frame: from start of study drug (week 0) to end of washout (week 108)
Core Protocol Secondary outcomes
9\. Safety and tolerability of treatment
Time frame: from start of study drug (week 0) to end of treatment (up to week 104)
Core Protocol Secondary outcomes
10\. Change in quality of life measured using the Quality of Life Impact Survey for Kidney Disease (QDISCKD) at 6-monthly intervals from randomisation to week 108.
Time frame: 6-monthly intervals from randomisation to week 108
MRA Domain Secondary Outcome
MRA DSA has a domain-specific secondary outcome that evaluates the time to the composite of ≥57% eGFR decline from week 0 or kidney failure
Time frame: from start of study drug (week 0) to end of washout (week 108)
GLP-1 RA Domain Secondary Outcome
1\. Change in eGFR slope from Week 0 to Week 108.
Time frame: from start of study drug (week 0) to end of washout (week 108)
GLP-1 RA Domain Secondary Outcome
2\. Time to composite of onset of kidney failure (initiation of long-term dialysis, kidney transplantation, or a reduction in the eGFR to \<15 mL per minute per 1.73 m2 sustained for ≥28 days), a sustained (for ≥28 days) 50% or greater reduction in eGFR from Week 0, or death from kidney-related or cardiovascular causes.
Time frame: from start of study drug (week 0) to end of washout (week 108)
GLP-1 RA Domain Secondary Outcome
3\. Time to first occurrence of onset of persistent ≥50% reduction in eGFR from Week 0 to Week 108
Time frame: from Week 0 to Week 108
GLP-1 RA Domain Secondary Outcome
4\. Time to first occurrence of a composite outcome of major adverse cardiovascular events (MACE) consisting of non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death
Time frame: from start of study drug (week 0) to end of washout (week 108)
GLP-1 RA Domain Secondary Outcome
5\. Time to occurrence of all-cause death
Time frame: from start of study drug (week 0) to end of washout (week 108)
GLP-1 RA Domain Secondary Outcome
6\. Change in body weight from Week 0 to Week 108
Time frame: from Week 0 to Week 108
GLP-1 RA Domain Secondary Outcome
7\. Change in HbA1c from Week 0 to Week 108
Time frame: Week 0 to Week 108
GLP-1 RA Domain Secondary Outcome
8\. Change in systolic blood/diastolic blood pressure from Week 0 to Week 108
Time frame: from Week 0 to Week 108
GLP-1 RA Domain Secondary Outcome
9\. Change in NT-proBNP from Week 0 to Week 108
Time frame: from Week 0 to Week 108
GLP-1 RA Domain Secondary Outcome
10\. Change in health status measured using the 23-item Kansas City Cardiomyopathy Questionnaire (KCCQ) at 6-monthly intervals from randomisation to Week 108
Time frame: from randomisation to Week 108
GLP-1 RA Domain Secondary Outcome
11\. Incidence of AEs and the following medical events of special interest (MESI) from Week 0 to end of trial: 1. Neoplasm (malignant and benign) 2. Pancreatitis, or persistent abdominal pain leading to a suspicion of pancreatitis 3. Acute gallstone disease (biliary colic or acute cholecystitis) 4. Thyroid disease 5. Cardiac arrhythmia (specifically, atrial fibrillation, atrial flutter, ventricular tachycardia, ventricular fibrillation, torsade de pointes, second degree heart block type 2, third degree heart block, and symptomatic bradycardia requiring pacemaker placement) 6. Severe hypoglycaemic episodes 7. Immunogenicity events (allergic reactions, immune-complex disease, and lack of efficacy) 8. Adverse events leading to treatment discontinuation (if not any of the mentioned MESIs) 9. Ocular adverse events 10. Suspicion of transmission of infectious agents
Time frame: Week 0 to end of trial
Not enrolling at this site — choose another above.
Plan to share: Yes — Trial data will be made available as a resource for future unspecified research, subject to any prior contractual obligations. Researchers wishing to gain access to the study resources will be required to submit an application for review by the Platform Oversight Committee, including a detailed project description, a list of data requested, and evidence of ethical approval. De-identified data extracts will be made available to approved proposals, and will not include data obtained from data linkage with local registries.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: TBC
Access criteria: Assessments of data requests will be based on sound science, benefit-risk balancing and research team expertise.
Started Sep 2024 (actual). Primary completion is estimated for Dec 2029, 63 months after the start.
Of 41 non-industry phase 3 interventional studies under Renal Insufficiency, Chronic, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 69. This study's planned 63 months is above that.
Counting every sponsor, half of 145 studies reached it within 32 months; a quarter within 19 and three quarters within 54.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 5, 2026: primary completion Aug 2028 → Dec 2029 and completion Mar 2029 → Dec 2029.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
…and 1 more changes, on the record history on ClinicalTrials.gov ↗
…and 1 more changes, on the record history on ClinicalTrials.gov ↗
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Finerenone · Semaglutide
Renal Insufficiency, Chronic →
The George Institute